Stocks Health care ARGX
NASDAQ · Health careArgenx SE (ARGX)
Operating cash flow minus capital spending left $679M of free cash flow in fiscal 2025. At December 31, 2025 it held $3.5B in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 19, 2026.
What Argenx SE does
argenx is a biotechnology company that develops antibody-based medications for autoimmune diseases and cancer. Its primary commercial product, efgartigimod, treats generalized myasthenia gravis, a condition causing severe muscle weakness. The company sells its prescription therapies directly to healthcare providers, hospitals, and pharmacies globally. Its shares trade on NASDAQ under the ticker ARGX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | $1.3B | $19.57 | $679M |
| 2024 | n/a | $833M | $12.78 | -$84.5M |
| 2023 | $35.5M | -$295.1M | -$5.16 | -$421.1M |
| 2022 | $10M | -$709.6M | -$13.05 | -$863.6M |
| 2021 | $497.3M | -$408.3M | -$7.99 | -$610.4M |
| 2021 | $41.2M | -$608.5M | -$13.40 | -$399.5M |
Latest SEC filings
What Argenx SE has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 27, 2026
- August 27, 2026Tender offer (amended) SC TO-T/A
- August 19, 2026Tender offer (amended) SC TO-T/A
- August 17, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Tender offer (amended) SC TO-T/A
- August 6, 2026Tender offer SC TO-T
- August 3, 2026
- July 28, 2026Form SC TO-C filing SC TO-C
- July 27, 2026Form SC TO-C filing SC TO-C
Questions about ARGX
What does Argenx SE do?
argenx is a biotechnology company that develops antibody-based medications for autoimmune diseases and cancer. Its primary commercial product, efgartigimod, treats generalized myasthenia gravis, a condition causing severe muscle weakness. The company sells its prescription therapies directly to healthcare providers, hospitals, and pharmacies globally. Its shares trade on NASDAQ under the ticker ARGX.
Is Argenx SE profitable?
Yes. In fiscal 2025 it reported net income of $1.3B.
When did Argenx SE last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 19, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from August 27, 2026.
Similar companies
Follow ARGX
Get an email when Argenx SE files with the SEC: results, executive changes, material agreements and annual reports.
Follow ARGX: get an email when it filesWhere the numbers come from
Financial figures are the values Argenx SE tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.